News

SNTA

King: How the Oncology Drug Development Machine Builds Biotech Wealth

The Life Sciences Report | Equities.com |

Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He


Synta (SNTA) Plunges on Lung Cancer Drug Results

Joel Anderson | Equities.com |

Shares in Synta Pharmaceuticals Corporation (SNTA) plunged over 20 percent Monday morning after early results from trials for its potential lung cancer drug failed to show significant results.


Stocks Under $10: More Hold-Rated Biomed/Genetics in the Medical Sector

Richard Suttmeier | Equities.com |

At www.ValuEngine.com we show that the Medical sector 12.1% overvalued with the Medical Biomed / Genetics 13.7% overvalued. All 17 stocks in today’s table have complete ValuEngine data and have


Equities Sector Coverage: Stocks End Flat Due to Late Sell-Off

Sector Recap | Equities.com |

Existing home sales rose by 3.4% in April to an annual rate 4.62 million units, the highest level since May 2010. The Dow Jones Industrial Average traded down to 12,483.21 then up to 12,575.96.


China Stocks Turn Lower after Mainland Re-Opens

Gene Linn | Equities.com |

So much for the New Year rally for China stocks. Investors now look to consumer plays for gains.The gateway market of Hong Kong posted a nice rise in the first trading day of 2012 on Tuesday, but


Sponsored Financial Content

Market Movers